NEW YORK, July 9 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that Dr. Robin Smith, the Company's Chairman and CEO, has been invited by Global Hunter Securities to present at the Global Hunter Securities ("GHS") China Conference.
Dr Smith commented, "China has become a central component of our overall growth strategy and we look forward to sharing recent developments in the region as well as our global initiatives to increase revenues, expand our adult stem cell collection and storage business and advance adult stem cell therapy in areas such as orthopedics, wound repair, and skin rejuvenation."
The GHS China Conference will be held on July 11 - 13, 2010 at the St. Regis Hotel in San Francisco. Dr. Smith is scheduled to make a presentation at 4 p.m. PT on Monday, July 12, 2010, and will be available to meet with investors throughout the conference.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com/ .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
NeoStem, Inc. CCG Investor Relations, Inc. Robin Smith, CEO Kalle Ahl, Account Manager Phone: +1 (212) 584-4174 Phone: +1 (646) 833-3417 E-mail: rsmith@neostem.com E-mail: kalle.ahl@ccgir.com http://www.neostem.com/ http://www.ccgirasia.com/ Crocker Coulson, President Phone: +1 (646) 213-1915 E-mail: crocker.coulson@ccgir.com
Neostem, Inc.
CONTACT: Robin Smith, CEO, NeoStem, Inc., +1-212-584-4174,
rsmith@neostem.com; Kalle Ahl, Account Manager, CCG Investor Relations, Inc.,
+1-646-833-3417, kalle.ahl@ccgir.com, or Crocker Coulson, President, CCG
Investor Relations, Inc., +1-646-213-1915, crocker.coulson@ccgir.com
Web Site: http://www.neostem.com/
